Business
New research project and CSO to return to academia
New research project and CSO to return to academia.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\")\n\nSkinBioTherapeutics initiates new Epiderm project in partnership\nwith the University of Manchester\nChief Scientific Officer, Prof. Cath O'Neill to move to Scientific Adviser role\n \n18 March 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the \"Company\"), the life science business focused on skin health, announces that it has initiated a research and development project with the University of Manchester, named the Epiderm project. The Company also announces that Professor Cath O'Neill has confirmed that she intends to stand down as Chief Scientific Officer (CSO) and move to a Scientific Adviser role.\n \nEpiDerm project with University of Manchester\n \nSkinBioTherapeutics has initiated a research and development project with the University of Manchester, named the Epiderm project (Epiderm). The project is in alignment with the Company's MediBiotix™ pillar, which targets the use of the SkinBiotix® technology for medical applications and commercialisation.\n \nThe project will be run by Professor Andrew McBain and Professor Sheena Cruickshank. Professor Andrew McBain co-created the SkinBiotix® technology and is an expert in the Microbiome. Professor Sheena is a Professor in Biomedical Sciences and Public Engagement at the University of Manchester and is a highly regarded figure in the field immunology.\n \nEpiderm will explore the use of a non-pathogenic ('friendly') skin bacterium with novel features that support barrier function in the skin. These friendly bacterium encourage the skin to heal by promoting the migration of skin cells, which help close up a wound.\n \nBy the end of the six month project, the aim will be to develop a technology derived from specific non-pathogenic skin bacterium that promotes wound healing.\n \nThe total budget for the project is £100k which will be joint funded by SkinBioTherapeutics and future grant funding.\nStuart Ashman, CEO of SkinBioTherapeutics said: \"The new Epiderm project is an exciting early step in furthering our work in the woundcare space and for our MediBiotix pillar. We are very pleased to continue our longstanding relationship with the University of Manchester and work alongside Professor Andrew McBain once again, as well as begin a new working relat...